Establishment of a Fermentation Facility

要求提供资金，以购置必要的仪器， 一个完整的细胞培养设施的发酵蛋白， 大学生物研究和技术研究所 来自南卡罗来纳州。 该设施将取代无法使用的28 L 发酵罐，并将提供广泛的发酵服务 大学社区。 用户组包括教师从 化学与生物科学系，以及 药学院和医学院。 项目的范围 该仪器支持的内容包括：（1）研究 血红素加氧酶的结构和功能;（2） 胸苷酸合成酶的机制研究;（3）胸苷酸合成酶的研究 哺乳动物基因表达;（4）研究胸苷酸合成酶， 氟嘧啶类药物的结构与功能研究 基质囊泡膜联蛋白;（6）用硒作为探针， 生物大分子的结构/功能;（7）检查生理学， 生态学和细菌功能群的进化;（8）研究 （9）基因作用机理 调节柄杆菌属;（10）大鼠精子细胞的结构研究 （11）检测抗肿瘤药物与抗肿瘤药物的相互作用。 药物azinomycin A和B与DNA;（12） 烯醇化酶;（13）枯草芽孢杆菌细胞分裂基因产物; (14)人乳头瘤病毒在人类肿瘤转化中的作用 细胞;（15）假尿苷在mRNA剪接中的形成和作用 辅因子;（16）人重组α-半乳糖苷酶的临床前评价 B/D杂合干扰素治疗肝炎和乳头瘤病毒 感染;和（17）整联蛋白及其与感染的相互作用。 细胞外基质

Funds are requested for instrumentation necessary to establish the fermentation protein of a complete Cell Culture Facility in the Institute for Biological Research and Technology at the University of South Carolina. This facility will replace an unusable 28 L fermenter, and will provide a wide range of fermentation services to the University community. The User Group includes faculty from the Department of Chemistry and Biological Sciences, as well as the College of Pharmacy and School of Medicine. The scope of projects to be supported by this instrumentation includes: (1) studies on the structure and function of hemeiron oxygenase enzymes; (2) mechanistic studies on thymidylate synthase; (3) studies on mammalian gene expression; (4) work on thymidylate synthase and fluoropyrimidine resistance; (5) structure function studies on matrix vesicle annexins; (6) using selenium as a probe of structure/function of biomacromolecules; (7) examining physiology, ecology, and evolution of bacterial functional group; (8) studies of the genetics of coal solubiolization; (9) mechanism of gene regulation in Caulobacter; (10) structural studies of rat spermatid transition protein 2; (11) examining the interaction of antitumor agents azinomycin A and B with DNA; (12) mechanistic studies of enolase; (13) cell division gene products of Bacillus subtilis; (14) role of human papillomaviruses in the transformation of human cells; (15) formation and role of pseudouridine in mRNA splicing cofactors; (16) preclinical evaluation of a human recombinant alph B/D hybrid interferon in therapy of hepatitis and papillomavirus infections; and (17) integrins and their interaction with the extracellular matrix.